The Center For Cancer and Blood Disorders

Summary

The Center For Cancer and Blood Disorders is a medical facility located in Fort Worth, Texas. This center is recognized for care of Breast Cancer, Lung Cancer, Pancreatic Cancer, Cancer, Non-Small Cell Lung Cancer and other specialties. The Center For Cancer and Blood Disorders is involved with conducting 101 clinical trials across 106 conditions. There are 2 research doctors associated with this hospital, such as Ray D Page and Robyn R Young, MD.

Top PIs

Clinical Trials running at The Center For Cancer and Blood Disorders

Breast Cancer

Bladder Cancer

Lung Cancer

Ovarian Cancer

Kidney Cancer

Chronic Lymphocytic Leukemia

Squamous Cell Carcinoma

Esophageal Cancer

Rectal Cancer

Non-Small Cell Lung Cancer

Sacituzumab Tirumotecan + Pembrolizumab

for Breast Cancer

The purpose of this study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physician's Choice (TPC) in participants with hormone receptor positive/human epidermal growth factor receptor-2 negative (HR+/HER2-) unresectable locally advanced, or metastatic, breast cancer. The primary hypotheses are that sacituzumab tirumotecan as a single agent and sacituzumab tirumotecan plus pembrolizumab are superior to TPC with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) by blinded independent central review (BICR) in all participants.

Recruiting

2 awards

Phase 3

3 criteria

Imlunestrant

for Early Breast Cancer

This trial is testing a new medication called imlunestrant to see if it works better than standard hormone treatments for certain breast cancer patients. The study focuses on patients with early-stage breast cancer that is estrogen receptor positive and HER2 negative, who have already been on hormone therapy for a period of time and are at high risk of their cancer returning. Imlunestrant works by blocking estrogen from helping cancer cells grow.

Recruiting

2 awards

Phase 3

6 criteria

Guardant Reveal

for Cancer

The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinical outcomes in order to demonstrate clinical validity for recurrence detection and explore its value in a healthcare environment subject to cost containment.

Recruiting

1 award

N/A

10 criteria